ublituximab (Briumvi)
Jump to navigation
Jump to search
Indications
- relapsing multiple sclerosis
Contraindications
- active hepatitis B infection
Adverse effects
- infusion-related reactions (48%)
- headache (34%)
- nasopharyngitis (18%)
- pyrexia (14%)
- nausea (11%)
- serious infections (5%)
- 3 deaths in clinical trials
- pneumonia
- encephalitis after measles
- salpingitis after an ectopic pregnancy[1]
- 3 deaths in clinical trials
* no cases of progressive multifocal leukoencephalopathy reported
Mechanism of action
- inhibits CD20
- triggers antibody-dependent cellular cytotoxicity & complement-dependent cytotoxicity leading to cell destruction.
More general terms
References
- ↑ 1.0 1.1 George J Anti-CD20 Agent Gains Approval for Multiple Sclerosis. FDA greenlights ublituximab for relapsing MS. MedPage Today December 29, 2022 https://www.medpagetoday.com/neurology/multiplesclerosis/102441
Steinman L, Fox E, Hartung HP et al Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med 2022; 387:704-714 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36001711 https://www.nejm.org/doi/full/10.1056/NEJMoa2201904